Stocks · News reference
This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Neutral on RDW, Overweight on ELOX, Buys on SGHT and AU, and Market Perform on FFIN.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Goldman Sachs Initiates Coverage On Anglogold Ashanti with Buy Rating, Announces Price Target of $104
Goldman Sachs analyst Matt Greene initiates coverage on Anglogold Ashanti (NYSE:AU) with a Buy rating and announces Price Target of $104.
Shares of precious metals-related companies are trading lower after stronger-than-expected inflation data boosted expectations for a Federal Reserve rate hike in October. Gold and silver prices are declining amid a stronger U.S. dollar and rising Treasury yields, which make non-yielding precious metals less attractive to investors.
Cantor Fitzgerald Initiates Coverage On Eloxx Pharma with Overweight Rating
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Overweight rating.
Leerink Partners Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $32
Leerink Partners analyst Joseph Schwartz initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $32.
Eloxx Pharmaceuticals Announces First Two Patients Dosed In Phase 2b EXACT Study Of Exaluren In Nonsense Mutation Alport Syndrome; Topline Data Expected Mid-2027